Yüklüyor......
Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies
[Image: see text] Inhibition of the androgen receptor (AR) is the mainstay treatment for advanced prostate cancer. Ralaniten (formally EPI-002) prevents AR transcriptional activity by binding to its N-terminal domain (NTD) which is essential for transcriptional activity. Ralaniten acetate (EPI-506)...
Kaydedildi:
| Yayımlandı: | ACS Pharmacol Transl Sci |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American
Chemical Society
2019
|
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7088963/ https://ncbi.nlm.nih.gov/pubmed/32259077 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.9b00065 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|